Evidence of oxidative stress as a cofactor in the development of insulin resistance in patients with chronic hepatitis C

Hepatology Research

Volumn 38, Issue 4, 2008, Pages 348-353

  Mitsuyoshi, Hironori ^a   Itoh, Yoshito ^a   Sumida, Yoshio ^b   Minami, Masahito ^a   Yasui, Kouichirou ^a   Nakashima, Toshiaki ^c   Okanoue, Takeshi ^d  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Nara City Hospital   (Japan)

^c Saiseikai Kyoto Hospital   (Japan)

^d Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

Author keywords

Hepatitis C virus; Insulin resistance; Oxidative stress; Steatosis; Thioredoxin

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; MESSENGER RNA; THIOREDOXIN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PHLEBOTOMY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM;

EID: 40049085583     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00280.x     Document Type: Article

References (25)

1. Dienstag JL, McHutchison JG. American gastroenterological association technical review on the management of hepatitis C. Gastroenterology 2006; 130: 231-64.
2. Weinman SA, Belalcazar LM, Hepatitis C. a metabolic liver disease. Gastroenterology 2004; 126: 917-19.
3. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: Relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002; 36: 729-36.
4. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004; 126: 586-97.
5. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
6. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-8.
7. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-94.
8. Zekry A, McHutchison JG, Diehl AM. Insulin resistance and steatosis in hepatitis C virus infection. Gut 2005; 54: 903-6.
9. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
10. Choi J, Ou JH. Mechanisms of liver injury III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol 2006; 290: 847-51.
11. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147-52.
12. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 2003; 52: 1-8.
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-19.
14. Sumida Y, Nakashima T, Yoh T et al. Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection. J Hepatol 2000; 33: 616-22.
15. Tsukiyama-Kohara K, Yamaguchi K, Maki N et al. Antigenicities of group I and II hepatitis C virus polypeptides -molecular basis of diagnosis. Virology 1993; 192: 430-7.
16. Searle JW, Kerr JFR, Halliday JW, Powell LW. Pathology of the Liver, 2nd edn. Edinburgh: Churchill Livingstone, 1987.
17. Kondo N, Nakamura H, Masutani H, Yodoi J. Redox regulation of human thioredoxin network. Antioxid Redox Signal 2006; 8: 1881-90.
18. Castera L, Hezode C, Roudot-Thoraval F et al. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: Indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut 2004; 53: 420-4.
19. Birnbaum MJ. Turning down insulin signaling. J Clin Invest 2001; 108: 655-9.
20. Kato J, Kobune M, Nakamura T et al. Normalization of elevated hepatic 8-hydroxy-2′-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res 2001; 61: 8697-702.
21. Korenaga M, Wang T, Li Y et al. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem 2005; 280: 37481-8.
22. Day CP. From fat to inflammation. Gastroenterology 2006; 130: 207-10.
23. Liu D, Liu J, Wen J. Elevation of hydrogen peroxide after spinal cable injury detected by using the Fenton reaction. Free Radic Biol Med 1999; 27: 478-82.
24. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991; 11: 81-128.
25. Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001; 35: 297-306.